TRADING UPDATES: East Star Verkhuba update; BSF distribution deal
11th Aug 2026 18:23
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
| Price | 0.85p on 01-10-2026 at 04:45:12 |
|---|---|
| Change | 0.00p 0% |
| Buy | 0.90p |
| Sell | 0.80p |
| Last Trade: | Sell 1,600,000.00 at 0.849p |
| Day's Volume: | 0 |
| Last Close: | 0.85p |
| Open: | 0.00p |
| ISIN: | GB0034330679 |
| Day's Range | 0.00p - 0.00p |
| 52wk Range: | 0.775p - 3.55p |
| Market Capitalisation: | £9.66m |
| VWAP: | 0.00p |
| Shares in Issue: | 1.14b |
Cellbxhealth (CLBX) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Sell* | 1,600,000 | 0.849p | Ordinary |
16:20:06 - 30-Sep-26 |
| Sell* | 50,000 | 0.845p | Ordinary |
16:08:07 - 30-Sep-26 |
| Sell* | 39,920 | 0.845p | Ordinary |
16:08:05 - 30-Sep-26 |
| Sell* | 42,000 | 0.8055p | Ordinary |
16:08:05 - 30-Sep-26 |
| Sell* | 5,000 | 0.845p | Ordinary |
15:53:28 - 30-Sep-26 |
| Sell* | 12,500 | 0.845p | Ordinary |
15:52:53 - 30-Sep-26 |
| Buy* | 118,573 | 0.84p | Ordinary |
15:50:55 - 30-Sep-26 |
| Buy* | 118,856 | 0.838p | Ordinary |
15:03:09 - 30-Sep-26 |
| Buy* | 200,000 | 0.838p | Ordinary |
15:02:11 - 30-Sep-26 |
| Buy* | 59,524 | 0.84p | Ordinary |
14:47:51 - 30-Sep-26 |
Cellbxhealth (CLBX) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 11th Aug 2026 7:00 am | RNS | Parsortix CTCs used for Brain Cancer detection |
| 3rd Aug 2026 7:00 am | RNS | Parsortix CTCs used for ADC target assessment |
| 16th Jul 2026 7:00 am | RNS | Issue of Share Options |
| 15th Jul 2026 7:00 am | RNS | Q2 and First Half Year Results ended 30 June 2026 |
| 14th Jul 2026 9:46 am | RNS | Result of AGM |
| 14th Jul 2026 7:00 am | RNS | AGM Statement |
| 6th Jul 2026 4:45 pm | RNS | Directorate change |
| 22nd Jun 2026 7:00 am | RNS | Preliminary Results |
| 16th Jun 2026 7:00 am | RNS | Notice of Results |
| 29th May 2026 7:00 am | RNS | MSA with Global Pharmaceutical Company |